During the global COVID-19 outbreak, BioEcho developed a rapid extraction protocol that reduced the isolation of SARS-CoV-2-RNA to just a few minutes. Currently, BioEcho offers a CE-marked viral RNA/DNA extraction kit and is implementing automated solutions that will allow customers to increase their diagnostics throughput.
SARS-CoV-2-antibodies may promote severe COVID-19
Latest NewsImmunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
Abingworth raises $582m for late-stage fund ACCD 2
Latest NewsInternational life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.
USA supports to temporarily waive IP of COVID-19 vaccines
Latest NewsThe Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.
Swiss Oculis SA raises $57m in Series C
Latest NewsTopical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.
New entrant at Celyad
AppointmentsBelgium-based Celyad has had a new CMO since April: Dr Charles Morris.
Mogrifiy completes Series A financing round
Latest NewsCell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.
COVID-19 vaccine for poor countries
Latest NewsModerna Inc. has signed a COVID-19 vaccine supply agreement with vaccination alliance Gavi.
Increase viral RNA extraction throughput with automation
Sponsored PublicationsDuring the global COVID-19 outbreak, BioEcho developed a rapid extraction protocol that reduced the isolation of SARS-CoV-2-RNA to just a few minutes. Currently, BioEcho offers a CE-marked viral RNA/DNA extraction kit and is implementing automated solutions that will allow customers to increase their diagnostics throughput.
ADCendo ApS raises €51m in Series A financing
Latest NewsDanish ADCendo ApS will use the funds from a Series A investment to advance Antibody-Drug Conjugates (ADCs) entering cancer cells through endocytic receptors.
New Kurma-Partner appointed
AppointmentsThe Venture Capital Company Kurma Partners, based in Paris and Munich, appointed Jean-Francois Rivassou as new Partner.